Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 136 results for sclerosis

  1. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  2. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

  3. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  4. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Despite...

  5. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes. Any...

  6. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive...

  7. Topic prioritisation

    Find out what guidance is being considered for development

  8. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (HTG235)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

  9. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable)...

  10. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  11. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  12. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced...

  13. Injectable bulking agents for faecal incontinence (HTG135)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.

  14. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476